-
-
-
-
-
-
-
Biogen and Denali discontinue Parkinson's drug after trial fails
-
-
-
-
-
-
-
Denali Therapeutics gains FDA approval for Hunter syndrome drug AVLAYAH
-
-
-
-
-
-
-
Denali Therapeutics secures $275 million royalty deal with Royalty Pharma
-
-
-
-
-
-
-
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
-
-
-
-
-
-
-
Denali Therapeutics (DNLI) Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) Tops Q1 EPS by 2c
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 199c
-
1,216,218 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

